InVivo Therapeutics Holdings Corporation (NVIV)
InVivo Therapeutics Holdings Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $0.32, down 34.28% on the session, giving a market capitalisation of $995,918. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of 0.0%. Its beta of 0.66 implies it has historically moved less than the broad market.
InVivo Therapeutics Holdings Corp. is a biotechnology and biomaterials firm, actively involved in research and clinical development. The company specializes in creating and bringing to market innovative biopolymer scaffolding devices designed to address spinal cord injuries (SCI). Its primary investigational product is the Neuro-Spinal Scaffold implant, a bioresorbable polymer scaffold. This device is engineered to be implanted directly at the site of injury within the spinal cord, aiming to treat acute SCI. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
InVivo Therapeutics Holdings Corporation is most often compared with the following Healthcare names: